Pharmaceuticals

VYNE Therapeutics

VYNE Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 169 K (forecast USD 100 K), actual EPS USD -0.17 (forecast USD -0.145)

VYNE Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 440K and EPS of USD -0.5064

VYNE Therapeutics released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 271K (forecast USD 300K), actual EPS USD -0.3363 (forecast USD -0.45)

VYNE Therapeutics released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 69K (forecast USD 150K), actual EPS USD -0.1345 (forecast USD -0.2233)

Vyne Therapeutics Inc Expected to Report a 22-Cent Loss Per Share

VYNE's Oral BET Inhibitor Trials Partially Relisted

VYNE Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 202 K (forecast USD 50 K), actual EPS USD -0.2017 (forecast USD -0.29)

VYNE Therapeutics Reports Q1 Earnings and Clinical Trial Updates

HC Wainwright Maintains Buy Rating on VYNE, Cuts Target Price

FDA Pauses VYNE Therapeutics' Psoriasis Plaque Study

VYNE Therapeutics released FY2024 Q4 earnings on March 6 (EST), actual revenue 84 K USD (forecast 140 K USD), actual EPS -0.2822 USD (forecast -0.3033 USD)

VYNE Therapeutics released FY2024 Annual Earnings on March 6 (EST), actual revenue 501 K USD (forecast 550 K USD), actual EPS -0.9353 USD (forecast -0.96 USD)

VYNE Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST) with actual revenue of USD 417K and EPS of USD -0.653

VYNE Therapeutics released FY2024 Q3 earnings on November 7 (EST), actual revenue 121K (forecast 110K), actual EPS -0.2854 (forecast -0.235)

Vyne Therapeutics announces the grant of a composition of matter patent for Vyn202

Vyne Therapeutics: Expected to Release Key Data in the Second Half of 2024.

Vyne Therapeutics announces first subject dosed in Phase 2B vitiligo trial

VYNE Therapeutics released FY2024 Q1 earnings on May 9, 2024 (EST), actual revenue USD 98 K (forecast USD 100 K), actual EPS USD -0.1467 (forecast USD -0.24)

VYNE Therapeutics released FY2023 Q4 earnings on February 29 (EST), actual revenue 76 K USD (forecast 150 K USD), actual EPS -0.2025 USD (forecast -0.5 USD)

VYNE Therapeutics released FY2023 9 Months Earnings on November 13, 2023 (EST) with actual revenue of USD 348K and EPS of USD -6.8053

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap